Pathstone Holdings
WST icon

Pathstone Holdings’s West Pharmaceutical WST Stock Holding History

Pathstone Holdings’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.7M Buy
24,202
+606
+3% +$185K 0.03% 454
2026
Q1 		$5.91M Buy
23,596
+1,280
+6% +$318K 0.02% 508
2025
Q4 		$6.14M Buy
22,316
+708
+3% +$194K 0.02% 488
2025
Q3 		$5.67M Buy
21,608
+522
+2% +$127K 0.02% 525
2025
Q2 		$4.61M Sell
21,086
-4,755
-18% -$1.02M 0.02% 570
2025
Q1 		$5.79M Buy
25,841
+2,230
+9% +$615K 0.03% 509
2024
Q4 		$7.73M Buy
23,611
+790
+3% +$249K 0.03% 402
2024
Q3 		$6.85M Sell
22,821
-1,420
-6% -$435K 0.03% 450
2024
Q2 		$7.98M Sell
24,241
-1,274
-5% -$450K 0.04% 375
2024
Q1 		$10.1M Buy
25,515
+10,870
+74% +$4.02M 0.05% 299
2023
Q4 		$5.16M Buy
+14,645
New +$5.18M 0.03% 430

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pathstone Holdings's WST Position: Q2 2026 in Review

Pathstone Holdings increased its West Pharmaceutical (WST) stake by 2.6% in Q2 2026, buying an estimated $185K and bringing the position to 24,202 shares worth $8.7M. The position accounts for 0.03% of the portfolio, ranked #454.

Pathstone Holdings first reported a position in WST in Q4 2023 and has held it in 11 quarters since. The position peaked at $10.1M in Q1 2024. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Pathstone Holdings held 24,202 shares of West Pharmaceutical worth $8.7M as of Q2 2026.
  • Pathstone Holdings bought 606 West Pharmaceutical shares in Q2 2026, an estimated $185K.
  • West Pharmaceutical made up 0.03% of Pathstone Holdings's portfolio in Q2 2026, its #454 holding.
  • Pathstone Holdings first reported a position in West Pharmaceutical in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's West Pharmaceutical position peaked at $10.1M in Q1 2024.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.